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Objective: Osteopontin (OPN) and osteoprotegerin (OPG) are well-known vascular calcification inhibitors, which have
been recently demonstrated to correlate with inflammation and cardiovascular events incidence. The aim of this
cross-sectional study is to survey whether OPN and OPG are involved in carotid plaque vulnerability. For this reason, we
assessed serum OPN and OPG levels in patients with carotid stenosis, and we explored their relationship with carotid
plaque echogenicity and subsequent cerebrovascular ischemic events.
Methods: A total of 164Whites were selected from a large cohort of 297 subjects to participate. In particular, 114 patients
(61 men, 53 women), aged 55 to 80, had recently-diagnosed ICA stenosis higher than 50%. A group of 50 age-, sex-, and
body mass index (BMI)-matched healthy individuals served as healthy controls. Patients with renal failure, hypothyroid-
ism, osteoporosis, and lipid-lowering therapy were excluded. Images of both carotids were obtained from all participants
using a high-resolution color duplex ultrasound and the gray-scale median (GSM) score was calculated. Brain computed
tomography (CT), and magnetic resonance imaging (MRI) scans when CT was questionable, were performed on all
patients with carotid stenosis. Clinical parameters, lipid and glycemic indexes, hsCRP, fibrinogen, white blood cells
(WBC) count, OPN, and OPG were measured. Independent t test, one-way ANOVA, Pearson correlation, and multiple
regression analysis were used for statistical analysis.
Results:Among patients with carotid stenosis, 60 had history of ipsilateral stroke or TIA and positive CT orMRI findings
(group A), while 54 had no neurological symptoms and negative CT and MRI scan (group B). Overall, patients with
carotid stenosis showed worse lipid profile and increased waist circumference, blood pressure, hsCRP, fibrinogen, WBC
count, OPN, and OPG levels compared with healthy subjects (group C) (P<.05). Statistical analysis revealed that group
A had significantly lower levels of GSM than group B (57.41  38.19 vs 76.32  36.72; P  .008) and higher levels of
hsCRP, OPN, andOPG than groups B and C (P< .05). Concerning the latter, biochemical markers group B showed only
elevated OPG levels compared with group C (P .038). Notably, GSMwas considerably associated with serumOPN and
OPG and waist circumference in patients with carotid atherosclerosis in univariate (r  0.333; P  .032, r  0.575;
P < .001, r  0.590; P .006, respectively) and multiple regression analysis (R2  0.445; P .006).
Conclusions: The present study demonstrated elevated serum OPN and OPG levels in patients with carotid stenosis and
documented an independent association between these biochemical markers, GSM and carotid-induced symptomatology.
Therefore bone-matrix proteins combined with GSM could be potential markers for vulnerable carotid plaques. ( J Vasc
Surg 2008;47:55-62.)Stroke is one of the most common causes of mortality
and disability in the Western world. It is well established
that carotid atherosclerosis highly predisposes to cerebral
ischemic events, and mounting evidence correlates carotid
plaque texture with its stability.1,2 Regarding imaging tech-
niques to assess carotid narrowing and carotid plaque com-
position, high-resolution ultrasound B-mode has become a
safe, noninvasive, and repeatable method. Most recently,
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doi:10.1016/j.jvs.2007.09.058the gray-scale median (GSM) score, a quantified index of
carotid plaque echogenicity, has emerged as a secondary
assessment methodology of carotid plaque vulnerability.3
Previous researchers have linked histopathological and ul-
trasonographic findings.4 In particular, they have docu-
mented that echolucent plaque comprises of greater lipid
content and hemorrhage than echogenic plaque that
mostly contains calcified and fibrous tissue, and it is associ-
ated with higher rate of cerebrovascular events.
Ectopic calcification constitutes a prominent feature of
several cardiovascular diseases, which is tightly regulated by
promoters and inhibitors.5 Although calcium deposition in
carotid plaque augments its stability, coronary artery calci-
fication is a more complex procedure.6 Quantitative assess-
ment of coronary calcification by electron-beam computed
tomography strongly predicts acute coronary syndromes
(ACS).7 On the other hand, intravascular ultrasound has
demonstrated that localized plaques from patients with
stable angina pectoris are more extensively calcified than
55
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that coronary artery tree calcification is a risk factor for
ACS, while coronary lesions calcification stabilizes athero-
sclerotic plaque and prevents ACS.
Osteopontin (OPN), a well-known calcification inhib-
itor, is expressed by many cell-types (osteoblasts, macro-
phages, etc) in response to biological stressors.9 Via signal-
ing functions, OPN inhibits mineral deposition and
regulates mineralized tissue turnover.10 Unlike bone, the
role of OPN in the arterial vasculature is poorly character-
ized. Although OPN is expressed by all aortic cells, includ-
ing activated macrophages of the atheroma, its involvement
in atherosclerosis progression is still speculative.11
Osteoprotegerin (OPG), a member of the tumor ne-
crosis factor-receptor family, inhibits osteoclastogenesis
and the osteoclastic bone resorption.12 In arterial vascula-
ture, smooth muscle cells and endothelial cells produce
OPG, but its precise role in vascular pathophysiology
remains obscure.13 In nonatherosclerotic artery, OPG
functions as an angio-protective factor by enhancing
immune defence, preventing endothelial cells apoptosis
and inhibiting vascular calcification.10 The inhibition of
receptor activator of nuclear factor-kB ligand (RANKL)
and tumor necrosis factor (TNF) -related apoptosis-induc-
ing ligand (TRAIL) mediate predominantly the above
functions.10 Contrary to the aforementioned protective
role, OPG has been positively associated with the presence
and severity of coronary artery disease,14 and the increased
risk of cardiovascular diseases in general population.15
Most recent evidence suggests that OPG counter-regulate
the atherosclerosis-induced mineralization of multipoten-
tial vascular cells and thus inhibits atherosclerotic. Further
studies are required.
Thus, the primary endpoints of the present study were
first to address the question of whether serum OPG and
OPN are associated with carotid atherosclerosis and subse-
quent cerebrovascular ischemic events and second, to test
the hypothesis that bone-regulators correlate with carotid
plaque echogenicity and thereby could be used as early
markers of vulnerable carotid plaques.
METHODS
Study design and subjects. The present, cross-
sectional, study was conducted from May 2005 to April
2007. It constitutes a part of an ongoing, prospective
project, which aims to identify patients with undiagnosed
carotid stenosis and provide optimal therapies. Therefore,
the following preliminary data represent the baseline char-
acteristics of our project population. The target population
was: (1) patients with recently-diagnosed stenosis, more
than 50%, of at least one internal carotid artery (ICA) and
(2) healthy subjects. After obtaining a written informed
consent, all participants underwent a diagnostic high-
resolution color duplex ultrasound of both carotids.
Patients with carotid stenosis were selected from a large
cohort of patients recently admitted to our hospitals due to
ischemic stroke, transient-ischemic attacks (TIAs), or am-
aurosis fugax. Candidates for carotid artery examinationwere also subjects with newly diagnosed peripheral arterial
disease, or patients attending our hospital out-patient de-
partments of diabetes, obesity, and hypertension with one
or more classical cardiovascular risk factors. In parallel, we
looked for healthy volunteers among subjects who had
visited our internal medicine department for reasons irrel-
evant to chronic diseases. All healthy subjects were free
from any chronic metabolic or cardiovascular disease. None
of them was receiving any long-term medication or was
suffering from an acute infection. Exclusion criteria were
life-threatening diseases, hypothyroidism, osteoporosis,
coronary artery disease, or overt cardiac-origin symptoms,
atrial fibrillation, and renal impairment (creatinine levels
2.0 mg/dl). Trying to limit drug confounders, we did not
recruit patients receiving systemic glucocorticoids, immu-
nosuppressants, bisphosphonates, lipid lowering therapy,
angiotensin II receptor blockers, estrogen therapy, and
warfarin which may affect OPN and OPG levels. Carotid
intimal thickening was considered as an exclusion reason
for healthy individuals.
In patients with carotid stenosis, the diagnosis of acute
ischemic stroke or TIA was based on the comparative
evaluation of medical history, neurological examination,
and brain computed tomography (CT) scan. The presence
of subcortical or cortical ischemic lesions in the territories
of carotid arteries was indicative of positive CT scan. When
CT findings were questionable, brain magnetic resonance
imaging (MRI) examination was additionally performed,
just to limit the possibility of misclassifying patients with
silent infarcts. After initial evaluation, eligible subjects were
categorized into group A, symptomatic patients with ca-
rotid stenosis, history of ipsilateral stroke or TIA and posi-
tive CT and/or MRI findings; group B, asymptomatic
patients with carotid stenosis, no focal neurological symp-
toms and negative CT and MRI; and group C, healthy
individuals. Patients with silent infarcts were assigned to
symptomatic group. In symptomatic patients, clinical ex-
amination and all imaging tests were performed during
their hospitalization.
Diabetes mellitus was considered to be present if a
patient fulfilled any of the criteria of diabetes diagnosis
(American Diabetes Association). Peripheral arterial dis-
ease, smoking habits, and parental medical history were
recorded using structured questionnaire.
A physical examination was performed and anthropo-
metrical parameters like body weight, height, waist and hip
circumferences, and waist-to-hip ratio (WHR) were ob-
tained from all participants. Body mass index (BMI) was
calculated as body weight in kilograms divided by the
square of the height in meters (kgr/m2). Blood pressure
was measured twice, after keeping participants at a sitting
position for 15 minutes. There was a 5-minute interval
between the two measurements and the mean value was
estimated.
The study protocol conformed to the ethical guidelines
of the Declaration of Helsinki and was approved by the
local ethical committees.
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Logiq700, Riverside, Calif) equipped with a 7.5 MHz
probe was used. Carotid artery was investigated bilaterally
in a suitable longitudinal or transverse view by the same
radiologist who was unaware of clinical and laboratory data.
Gray-scale and color Doppler images were used in diagno-
sis and grading of ICA stenosis according to the recom-
mendations of the Society of Radiologists in Ultrasound.16
All examinations and measurements of plaques were di-
rectly recorded on a personal computer and were per-
formed by a single observer blinded to patients’ history.
Texture analysis of manually selected plaque areas was
performed using ANALYSIS, an integrated software system
designed to assist interpretation of medical images and
GSM was calculated17. Normalization of GSM was per-
formed according to the procedures described by Elatrozy
et al.18 Specifically, the images were normalized manually
by linearly adjusting the image so that the GSM value of the
blood was 0-5 and the GSM value of the adventitia 180 to
190.
In group A, the GSM value of the culprit plaque
associated with the ipsilateral brain infarct was used for the
study purposes. In case of more than one unilateral athero-
sclerotic plaque, we measured GSM of each plaque and
then averaged the echodensity of these plaques. In asymp-
tomatic patients with more than one carotid plaque, GSM
of each single plaque was estimated and the average value
was considered for statistical analysis.
Blood analyses. Blood samples were obtained be-
tween 8 AM and 9 AM after an overnight fast. In order to
restrict the effects of time since event on biochemical
markers, we obtained blood samples from symptomatic
group at the same time period: 14 days after admission to
the hospital and at least 7 days after discharge from the
hospital. Glucose and lipid parameters were determined
using standard enzymatic methods (Olympus AU560,
Hamburg, Germany). High-sensitivity C-reactive protein
(hsCRP) and fibrinogen were measured by nephelometric
assay (Dade Behrin, BNII, Marburg, Germany) and the
Clauss method, respectively. Plasma OPN and OPG were
assayed using quantikine immunoassay ELISA kits (R&D
Systems Inc, Minneapolis, Minn, and BioVendor Labora-
tory Medicine Inc, Modrice, Czech Republic). The intra-
and inter-assay coefficients of variance were 2.6% and 5.7%
for OPN and 7% and 6.8% for OPG, respectively. Samples
were frozen and stored (80°C) until analysis in the same
assay.
Statistical analysis. Results are presented as means 
SD. Comparison between groups was performed by stu-
dent t test and one-way ANOVA for parametric parameters.
2 test and Mann-Whitney U test was used for nonpara-
metric differences. For multiple comparisons, significant
values were adjusted using the Bonferroni method. Nor-
mality of distribution was assessed by the Kolmogorov-
Smirnov test. Univariate correlations of continuous vari-
ables were examined by Pearson’s correlation analysis.
Partial correlations were used to adjust for age. Multiple
regression analysis was conducted to evaluate the relativecontributions made by each variable to GSM. All analyses
were carried out by software SPSS (13.0 version, SPSS Inc,
Chicago, Ill). The chosen significance level was a two-tailed
P  .05.
RESULTS
At initial screening, significant carotid atherosclerotic
lesions were found in 225 patients. Regarding selection
criteria, 114 of them were finally considered eligible for our
study. On the other hand, 72 healthy individuals were
identified and subscribed to participate in our study. From
the latter population a body of 50 age-, sex-, and body-mass
index (BMI)-matched healthy volunteers was finally in-
cluded for statistical analysis. Totally, 164 Caucasian pa-
tients (90men and 74women) were included in the present
study. All carotid ultrasound images were of good quality,
and therefore, they were concerned for statistical analysis.
The ultrasound criteria of the degree of carotid stenosis
have been validated in our hospitals’ cohort and conform to
international recommendations.17
The characteristics of all participants are listed in Table I.
Patients with carotid stenosis matched healthy subjects in
blood pressure and smoking habits, but they differed in
waist circumference and WHR (P  .05). We detected
increased mean fasting plasma glucose, total cholesterol,
and LDL concentrations and lower levels of HDL in pa-
tients with carotid stenosis than healthy individuals (P 
.05). Hyperglycemia observed in the carotid group was
attributed to the inclusion of diabetic patients (26.32%)
and their moderate glycemic regulation. Moreover, the
concentrations of inflammatory markers such as hsCRP,
fibrinogen, white blood cells (WBC) count, and vascular
calcification inhibitors were considerably increased in pa-
tients with carotid stenosis compared with control subjects
(P .001). We then examined the influence of diabetes on
inflammatory and bone-matrix markers, and we identified
higher levels of them in the diabetic subpopulation. How-
ever, after the exclusion of diabetic patients from statistical
analysis, the differences between nondiabetic subgroup and
healthy subjects were modestly decreased, without altering
the level of significance (data not shown).
Among patients with carotid stenosis, 60 presented
with neurological disorders or history of neurological
symptoms and positive brain imaging findings (symptom-
atic, group A) and 54 had no clinical and imaging evidence
of cerebral ischemic attack (asymptomatic, group B). Three
patients with carotid stenosis reported transient neurological
symptoms (amaurosis fugax or dysarthria), which passed be-
fore their admission to the hospital. Those patients after
thorough examination appeared without residual neuro-
logical derangements and negative brain CT and MRI
scans. Their symptoms were attributed to conditions other
than acute ischemic attacks and, thus, they were assigned to
asymptomatic group.
We did not detect significant differences between
symptomatic and asymptomatic patients in clinical param-
eters, lipid profile, blood pressure, fibrinogen, and WBC
count, while we found increased levels of hsCRP (P 
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than asymptomatic group (Table II). As well, the degree of
carotid stenosis did not differ between groups significantly.
Using one-way ANOVA analysis, we investigated differ-
ences in hsCRP, OPN, and OPG levels between symptom-
atic, asymptomatic, and healthy individuals. These three
groups were age-, sex-, and BMI-matched. At post-hoc
analysis, symptomatic patients appeared with significantly
higher levels of serum hsCRP, OPN, and OPG than asymp-
tomatic counterparts (P  .041, P  .046, and P  .016,
respectively) and healthy subjects (P  .026, P .004, and
P  .001, respectively). In comparison with healthy con-
trols, asymptomatic patients showed non-statistically
significant higher levels of hsCRP (2.93  1.95 mg/L vs
1.68  0.93mg/L; P  .329) and OPN (62.83 
41.81ng/ml vs 43.57  29.63 ng/ml; P  .069), but
considerably elevated levels of OPG (6.78 
2.05pmol/L vs 5.74  2.39pmol/L; P  .038) (Fig 1).
Correlations. In the total study population, univariate
analysis revealed that OPN was positively correlated with
OPG, age, total cholesterol, and LDL and inversely with
HDL and GSM (P  .05). Notably, the relationship be-
tween serum OPN and lipid parameters was lost after
adjustment for age (total cholesterol: P  .120, LDL: P 
.329, HDL: P  .540). Besides OPN, age, hsCRP, BMI,
and GSM value were also related to OPG. Adjustment for
age attenuated the relationship between OPG and BMI
(P  .255). Most importantly, the computerized marker of
plaque echogenicity was strongly associated with bone-
remodeling proteins, waist circumference, and WHR (P 
Table I. General characteristics of patients with carotid at
Variables Carotid atherosc
Number 114
Males /Females 61/53
Smokers (%) 23 (20.18%
Diabetes (%) 30 (26.32)
Antihypertensive regimen (%) 46 (40.35%
PAD 13 (11.4%)
Age (y) 67.57  6.55
BMI (kg/m2) 27.59  3.48
Waist circumference (cm) 96.92  9.01
WHR 0.95  0.08
Systolic BP (mm Hg) 132.25  16.1
Diastolic BP (mm Hg) 78.31  7.94
Total cholesterol (mg/dl) 237.74  41.6
HDL (mg/dl) 41.92  12.4
LDL (mg/dl) 161.37  35.7
Triglycerides (mg/dl) 164.32  90.4
FPG (mg/dl) 128.28  40.9
hsCRP (mg/L) 3.94  2.48
WBC (cells/L) 7164  1899
Fibrinogen (mg/dl) 421.19  132.
Osteopontin (ng/ml) 71.33  45.3
Osteoprotegerin (pmol/L) 8.00  3.47
PAD, Peripheral artery disease; BMI, body mass index; WHR, waist hip
C-reactive protein; WBC, white blood cells.
Data are means  SD..05) (Table III). No other significant relationships wereidentified between OPN, OPG, GSM, and the rest of study
variables.
Multiple regression analysis was then performed to
evaluate the above correlations. We observed that GSM
retained an independent association with waist circumfer-
ence, OPN, and OPG levels (R2  0.445; P .006). We
also used multilinear regression analysis for the rest of the
above associations as well. We found that OPN, GSM, and
hsCRP constituted independent predictors of OPG after
entering multiple regression model (R2  0.552; P 
.011).
DISCUSSION
In the present cross-sectional study, patients with ca-
rotid atherosclerosis presented with worse lipid profile,
increased inflammatory markers (hsCRP, fibrinogen,
WBC), and elevated serum OPN and OPG levels than
healthy individuals. The latter biochemical markers showed
statistically significant difference between symptomatic and
asymptomatic patients with carotid stenosis, and they were
independently associated with carotid plaque echogenicity.
These data implicate the contributory role of vascular cal-
cification inhibitors to carotid atherosclerosis and plaque
stability. In parallel, the independent association of waist
circumference with GSM is a promising result with clinical
relevance.
OPN is a noncollagenous adhesive protein that increases
considerably across coronary artery disease severity. 19 Previ-
ous investigators argued that serum OPN is independently
associated with early carotid atherosclerosis.20 Our study
sclerosis and healthy subjects
Healthy control P
50
29/20 .598
11 (22%) .766
—
—
—
65.39  8.88 .846
28.15  3.60 .377
93.54  12.53 .012
0.92  0.09 .039
128.67  16.13 .214
81.22  9.98 .082
215.55  51.62 .014
47.68  12.39 .007
140.71  42.91 .014
142.32  60.34 .141
87.38  11.82 .001
1.68  0.93 .003
6495  1549.24 .046
319.48  95.95 .001
43.57  29.63 .008
5.74  2.39 .002
BP, blood pressure; FPG, fasting plasma glucose; hsCRP, high sensitivityhero
lerosis
)
)
0
3
7
8
2
7
.46
61
5
ratio;extended those findings by demonstrating a 63.71% incre-
B, Asymptomatic group. C, Healthy individuals.
Data are means  SD.
*HbA1c: comparison only between diabetic patients.
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Up to now, the atherogenesis-related mechanisms of OPN
were poorly understood. The transgenic overexpression of
OPN in high-fat fed C57BL/6 mice resulted in exacer-
bated atherosclerotic lesions formation,21 while the simul-
taneous deficiency of apolipoprotein E and OPN attenu-
ated atherosclerosis only in female mice.22 OPN functions
as a proinflammatory cytokine and augments monocyte/
macrophage activation.23 In addition to this, OPN medi-
ates Th1 immunity and triggers vascular smooth muscle
cells proliferation and migration.24 The above effects are
integral to atherosclerosis development and thereby may
precipitate atherosclerosis progression.
Most recently Golledge et al observed a fourfold higher
OPN expression in carotid specimens from symptomatic
patients compared with asymptomatic counterparts.25
These researchers observed the colocalization of OPN at
sites of inflammation. In our investigation, serum OPN
levels were significantly increased in symptomatic than
asymptomatic patients with carotid stenosis. Moreover, we
demonstrated for first time, an inverse correlation between
serum OPN levels and GSM value. Carotid echolucent
plaques, prone to rupture, have lower content of calcifica-
tion than echogenic plaques.4 Our findings collectively
support the notion that OPN down- regulates plaque cal-
cification and may promote plaque instability. Aside from
direct effects, OPN may facilitate plaque destabilization
indirectly. Available data suggest that OPN may induce
matrix metalloproteinases release and angiogenesis within
symptomatic patients with carotid atherosclerosis
Asymptomatic patients P
54
31/23 NS
12 (22.2%) 0.956
17 (31.48%) 0.262
18 (33.33%) 0.195
6 (11.11%) 0.872
65.93  7.12 .77
28.12  3.51 .183
96.74  9.43 .875
0.94  0.10 .465
130.98  14.54 .494
78.17  6.69 .876
136.71  49.99 .092
6.8  1.42 .470
215.29  50.64 .966
43.68  14.27 .220
141.73  43.93 .837
148.84  54.58 .137
2.93  1.95 .046
7388  2099.80 .333
410.35  135.27 .465
76.32  36.72 .008
62.6  8.68 .124
HR, waist hip ratio; BP, blood pressure; FPG, fasting plasma glucose;
y-scale median.Fig 1. Serum OPN and OPG concentrations in symptomatic,
asymptomatic, and healthy control group. A, Symptomatic group.Table II. Comparison of variables between symptomatic and a
Variables Symptomatic patients
Number 60
Males/females 37/23
Smokers (%) 11 (18.33%)
Diabetes (%) 13 (21.67%)
Antihypertensive regimen (%) 28 (46.67%)
PAD (%) 7 (11.67%)
Age (y) 68.91  5.79
BMI (kg/m2) 27.11  3.42
Waist circumference (cm) 97.08  8.72
WHR 0.96  0.07
Systolic BP (mm Hg) 133.33  17.39
Diastolic BP (mm Hg) 78.44  8.94
FPG (mg/dl) 120.84  29.56
*HbA1c (%) 6.52  1.15
Cholesterol (mg/dl) 215.80  53.18
HDL (mg/dl) 40.16  10.26
LDL (mg/dl) 139.68  42.43
Triglycerides (mg/dl) 179.03  113.41
hsCRP (mg/L) 4.49  2.09
WBC (cells/L) 6972  1710.38
Fibrinogen (mg/dl) 432.92  130.55
GSM 57.41  38.19
Carotid stenosis (%) 71.5  10.23
NS, Nonsignificant; PAD, peripheral artery disease; BMI, body mass index; W
hsCRP, high sensitivity C-reactive protein; WBC, white blood cells; GSM, grathe atherosclerotic plaque leading to fibrous cap degrada-
y C-re
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gether, OPN seems to assume a key role in atherogenesis
and cerebral ischemic events occurrence, but the underly-
ing mechanisms require further research.
The implication of OPG in human cardiovascular dis-
eases has been increasingly recognized.15 Although the
relation of OPG with stroke incidence is under investiga-
tion our patients with stroke or TIA appeared with elevated
serum OPG levels.5,29 In agreement with a recent study, we
found increased serum OPG levels in patients with carotid
stenosis than healthy subjects and strong association be-
tween OPG and carotid plaque echogenicity, even after
adjustment for age.30 Furthermore, serum OPG was grad-
ually increased across healthy, asymptomatic and symp-
tomatic subgroups, which reinforces its relationship with
carotid disease severity. The latter is subject of contro-
versy, and it may be attributed to different selection
criteria.15,25,30 For instance, we recruited patients with
significant carotid stenosis, whereas Vik et al conducted a
population health study with small proportion of patients
suffering from cardiovascular diseases.30 They also included
control subjects with numerous comorbidities (eg, diabe-
tes, hypertension, etc), which might have attenuated the
difference between groups.
OPG has been hypothesized to be a compensatory
vasculoprotective response to injurious stimuli of excessive
activated inflammatory pathways.15,29 Up to now, there are
conflicting results about the relationship between serum
OPG and inflammatory markers.14,29,31,32 In our study,
OPG correlated significantly with hsCRP implicating the
interference between OPG and inflammatory atheroscle-
rotic process. hsCRP is a surrogate marker of cardiovascular
events and such a relationship is of clinical importance.
Whether high serum OPG levels counter-regulate vascular
inflammation or constitute an epiphenomenon of inflam-
matory process remain to be verified.
OPG comprises a crucial inhibitor of vascular calcifica-
tion. OPG-deficient mice exhibit severe osteoporosis and
vascular calcification of the aorta and renal arteries.33 This
Table III. Correlations of serum osteopontin, osteoprote
Variables
Osteopontin
r P
Osteopontin (ng/ml) — —
Osteoprotegerin (pmol/L) 0.575 .001
GSM 0.333 .032
Age (y) 0.289 .009
BMI (kg/m2) 0.242 .031
Waist circumference (cm) 0.310 .109
FPG (mg/dl) 0.158 .181
Total cholesterol (mg/dl) 0.360 .002
LDL (mg/dl) 0.298 .011
HDL (mg/dl) 0.208 .077
Triglycerides (mg/dl) 0.172 .145
hsCRP (mg/L) 0.325 .394
BMI, Body mass index; FPG, fasting plasma glucose; hsCRP, high sensitivitphenotype can be prevented by delivery of the recombinantOPG and transgenic overexpression of OPG.34 Conse-
quently, the elevated OPG levels in our symptomatic pa-
tients and their independent relationship with GSM sug-
gested less calcification and a contributory role of OPG to
plaque vulnerability. Probably targeting OPG may provide
a novel therapeutic strategy against carotid plaque rupture.
It is widely recognized that waist circumference is more
closely associated with abdominal visceral adipose tissue
accumulation and its consequences than other indexes of
adiposity.35 Centralized body fat predisposes to meta-
bolic disorders (eg, diabetes), cardiovascular diseases,
and constitutes the prevailing source of numerous cyto-
kines, which may influence carotid plaque stability.36 We
and others observed greater WHR and waist circumfer-
ence in patients with carotid stenosis than healthy BMI-
matched subjects.37 We also demonstrated an independent
relation between waist girth and carotid plaque echolu-
cency. Future studies combining carotid ultrasound and
precise assessments of abdominal obesity (CT, DEXA) will
unravel the interaction between fat derivatives (eg, adipo-
cytokines) and carotid plaque stability.
Finally, the expression of both bone-regulators is
highly induced by glucose.38 In agreement with previous
researches, higher serumOPN andOPG levels were found in
diabetic patients, suggesting that they may be involved in the
accelerated atherosclerosis seen in diabetes.30,39 However, we
showed a faint influence of diabetes on the differences be-
tween groups, which means a sustained involvement of calci-
fication inhibitors in atherosclerosis independent of diabetes
presence.
The principal limitation of our study is the cross-
sectional design, which prevents from defining a strong
causal relationship. A second limitation is the relative small
sample. However, we used numerous selection criteria, and
thus, our study sample was adequately homogeneous. Pa-
tients were recruited from a cohort of patients with newly-
diagnosed cardiovascular diseases and subjects clustering
cardiovascular risk factors. Thus, the upregulated levels of
bone-remodeling proteins should be interpreted in the
and GSM value with cardiovascular risk factors
Osteoprotegerin GSM
R P r P
0.575 .001 0.333 .032
— — 0.479 .033
0.479 .033 — —
0.499 .001 0.159 .491
0.243 .035 0.336 .156
0.092 .641 0.590 .006
0.252 .035 0.225 .402
0.370 .766 0.231 .408
0.027 .829 0.150 .593
0.110 .370 0.068 .811
0.119 .328 0.389 .151
0.311 .045 0.449 .179
active protein; GSM, gray-scale median.gerinframework of generalized atherosclerosis. Perhaps a study
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ferent results. Finally, we cannot rule out the presence of
patients with hidden bone metabolic perturbations in our
study, despite the exclusion of patients with diagnosed
osteoporosis.
Several points of our study should be considered. In
our study, the difference between symptomatic and asymp-
tomatic patients in the degree of carotid stenosis did not
reach statistical significance. A plausible explanation derives
from the small sample and the inclusion of patients with
stenosis 50%. The vast majority of our participants had
intermediate degree of stenosis (50%-69%), which might
have also attenuated the above difference between groups.
In parallel, biochemical markers capability to predict ca-
rotid plaque vulnerability and their cut-off points remain to
be determined by longitudinal studies. It is well-known
that biochemical markers alone are of low predictive power.
However, their combination with a valid spectrum of GSM
measurements would be valuable mediators of effective risk
stratification of patients with carotid stenosis. Finally, we
must explain how we succeeded to find a large number of
patients with carotid stenosis not receiving lipid-lowering
therapy at the entry of the study. First, our patients had
recently diagnosed carotid stenosis. Second, a small part of
them with dyslipidemia had not complied with their physi-
cians’ recommendations. Overall patients with carotid ste-
nosis are usually under-treated and patients with recent
stroke/TIA are under investigated for carotid stenosis, as
previous authors have referred.40
In conclusion, the present study outlined the increased
serum OPN and OPG concentrations in patients with
carotid atherosclerosis and their independent association
with carotid plaque echodensity and neurological symp-
tomatology. GSM and bone-regulators may help to iden-
tify potentially unstable plaques that most benefit from
intervention. Future prospective studies inquiring the ef-
fects of pharmaceutical and surgical interventions on bone-
matrix proteins will elucidate their role in long-term car-
diovascular outcomes.
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